Translations:Anti-obesity medication/13/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
FuzzyBot (talk | contribs)
15,162 edits
Importing a new version from external source
Tags: Mobile edit Mobile web edit
 
(No difference)

Latest revision as of 18:16, 7 March 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (Anti-obesity medication)
The [[American Academy of Pediatrics]] had not previously supported the use of weight loss medication in adolescents but issued new guidelines in 2023. It now recommends considering the use of weight loss medication in some overweight children aged 12 or older. The [[European Medicines Agency]] has approved semaglutide for children aged 12 or older who have a BMI in the 95 percentile for their age and a weight of at least {{convert|60|kg}}. However, GLP-1 agonists may not be cost effective in this population.

The American Academy of Pediatrics had not previously supported the use of weight loss medication in adolescents but issued new guidelines in 2023. It now recommends considering the use of weight loss medication in some overweight children aged 12 or older. The European Medicines Agency has approved semaglutide for children aged 12 or older who have a BMI in the 95 percentile for their age and a weight of at least 60 kilograms (130 lb). However, GLP-1 agonists may not be cost effective in this population.

Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:Anti-obesity_medication/13/en&oldid=125269"